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There is compelling evidence that inflammation contributes to tumorigenesis. Inflammatory 
mediators within the tumor microenvironment can either promote an antitumor immune 
response or support tumor pathogenesis. Therefore, it is critical to determine the rela-
tive contribution of tumor-associated inflammatory pathways to cancer development. 
Interleukin-33 (IL-33) is a member of the IL-1 family of cytokines that is released upon 
tissue stress or damage to operate as an alarmin. IL-33 has been primarily implicated 
in the induction of type-2 immune responses. However, recent findings have shown 
a role of IL-33 in several cancers where it may exert multiple functions. In this review, 
we will present the current knowledge on the role of IL-33 in the microenvironment of 
different tumors. We will highlight which cells produce and which cells are activated by 
IL-33 in cancer. Furthermore, we will explain how IL-33 modulates the tumor-associated 
inflammatory microenvironment to restrain or promote tumorigenesis. Finally, we will 
discuss the issues to be addressed first before potentially targeting the IL-33 pathway 
for cancer therapy.
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iNTRODUCTiON
Cancer is a heterogeneous disease and represents one of the leading causes of death worldwide. 
The process generally underlying cancer development was described as the “hallmarks” of cancer 
(1, 2). These hallmarks include self-sufficient proliferation, insensitivity to antiapoptotic signals, 
evasion of apoptosis, unlimited replication, maintenance of vascularization, and ability for invasion 
and metastasis. The so-called tumor microenvironment is also important for tumorigenesis, which 
supports the hallmarks of cancer. The concept of the tumor microenvironment implies that cancer 
cells alone are not able to manifest the disease but rather involve resident non-malignant cells or 
recruit them to participate to tumor development. The interactions between the cancer cells and 
Abbreviations: AOM, azoxymethane; BM, bone marrow; DC(s), dendritic cell(s); CAC, colitis-associated (colorectal) cancer; 
CAF(s), cancer-associated fibroblast(s); CCA, cholangiocarcinoma; cDC(s), conventional dendritic cell(s); CRC, colorectal 
cancer; CTL(s), cytotoxic T lymphocytes; DSS, dextran sodium sulfate; EGF, epidermal growth factor; EGFR, epidermal growth 
factor receptor; HCC, hepatocellular carcinoma; HNSCC, head and neck squamous cancer; HSPC(s), hematopoietic stem/pro-
genitor cell(s); IBD, inflammatory bowel disease; IL, interleukin; ILC(s), innate lymphoid cell(s); MDSC(s), myeloid-derived 
suppressor cell(s); MMP, metalloprotease; NK, natural killer cells; NSCLC, non-small-cell lung cancer; pDC(s), plasmacytoid 
dendritic cell(s); PDGF, platelet-derived growth factor; sST2, soluble form of ST2; TNF, tumor necrosis factor; Treg(s), regulatory 
T cell(s); VEGF, vascular endothelial growth factor; WT, wild type.
FiGURe 1 | interleukin-33 (iL-33)/ST2 signaling pathway. IL-33 is mainly 
expressed in the nucleus of epithelial and endothelial cells. IL-33 is released 
subsequent to cell damage, stress, or necrosis. Alternatively, IL-33 may be 
released under steady-state conditions—at low levels—via a so far unknown 
mechanism. Soluble IL-33 binds to its receptor, a heterodimeric complex 
comprising IL-1RL1/ST2 (ST2) and IL-1 receptor accessory protein (IL1RAP), 
thereby mobilizing downstream signaling molecules including MyD88 and 
TRAF-6, and eventually activating NF-κB, p38, JNK, and ERK pathways. 
Soluble ST2 acts as a decoy receptor for IL-33 to negatively regulate IL-33/
ST2 signaling.
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their supporting stroma result in the formation of tumors and 
local invasions, metastasis, or vascular niches promoting malig-
nancies (3). The tumor microenvironment consists of immune 
cells, endothelial cells, pericytes, fibroblasts, and smooth muscle 
cells (4, 5).
In addition to the occurrence of somatic “driver” mutations 
in transformed cells, long-term exposure to various environ-
mental stresses, and certain diets may contribute to tumor 
development (6). Meanwhile, it is also widely accepted that 
inflammation has an important impact on tumorigenesis (4). 
The developing tumor itself can promote antitumor immune 
responses, which is mainly executed by cytotoxic T lympho-
cytes (CTLs), natural killer cells (NK), but also T helper 1 cells. 
However, local mechanisms of immune suppression specific to 
the tumor may blunt these tumor-infiltrating immune effec-
tors (7–9). In addition, inflammatory stimuli may also exert 
a pro-tumorigenic action. Indeed, about 15% of malignancies 
are associated with microbes and a subsequent state of chronic 
inflammation (10, 11). Helicobacter pylori, human papilloma-
virus, hepatitis virus B and C, as well as cytomegalovirus and 
Epstein–Barr virus have been related to gastric cancer, cervical 
cancer, hepatocellular carcinoma (HCC), and hematologic 
malignancies, respectively. Patients suffering from inflamma-
tory bowel diseases (IBDs) have an increased risk of developing 
colorectal carcinomas (12, 13). Therefore, immune cells and 
inflammatory mediators are important components of the local 
environment of tumors (14).
Cytokines are central mediators of the interaction between 
cells in the inflammatory tumor microenvironment (15). 
Interleukin-33 (IL-33) is a member of the IL-1 family of cytokines. 
In contrast to other IL-1 family members like IL-1β and IL-18, 
IL-33 is inactivated upon caspase cleavage (16, 17). While full-
length IL-33 is already biologically active, its activity is enhanced 
~10-fold upon cleavage by neutrophil serine proteases cathepsin 
G and elastase (18). Full-length IL-33 is mainly expressed by 
epithelial and endothelial cells, where it is stored and bound to 
the chromatin in the nucleus (19, 20). IL-33 may exert a dual 
function, as damage-associated molecular pattern (DAMP) and 
cytokine (21), or as nuclear factor modulating gene expression 
(22). Full-length IL-33 acts as “alarmin” if released extracellularly, 
subsequent to cell stress or damage. Soluble IL-33 binds to its 
receptor, a heterodimeric complex comprising IL-1RL1/ST2 
(which is encoded by IL1RL1) and IL-1 receptor accessory protein 
(which is encoded by IL1RAP). IL-33/ST2 signaling is transduced 
via recruitment of MyD88 and IL-1 receptor-associated kinase-4 
(IRAK-4), downstream adaptor proteins shared with other 
IL-1 family members and with most Toll-like receptors (TLRs) 
(Figure 1). In addition, a soluble form of ST2 (sST2) exists, which 
is produced by alternative promoter usage, 3′ processing or dif-
ferential splicing and that may function as a decoy receptor for 
IL-33 (19, 23–25). IL-33 is primarily known as a driver of type-2 
immune responses, triggering the release of Th2 cytokines and 
thereby promoting allergic reactions (26). Moreover, IL-33 sup-
ports tissue repair by coordinating the action of innate lymphoid 
cells (ILCs) and regulatory T cells (Tregs) (27–30). Yet, IL-33 may 
also be involved in pathologic wound repair and fibrosis (31–34). 
Finally, recent findings have revealed an important contribution 
of IL-33 to several cancers, where it may exert pro and—less 
frequently—anti-tumorigenic functions (35).
Here, we review the current knowledge about the role of 
IL-33 in the microenvironment of different types of tumors. 
Each cancer type is presented according to the following 
scheme: (1) short introduction to the specific cancer type; (2) 
net effect of IL-33/ST2 signaling for tumorigenesis; (3) origin of 
IL-33- and ST2-expressing cells in the tumor stroma of a par-
ticular cancer type; (4) mechanisms of action of IL-33; and (5) 
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therapeutic opportunities. Furthermore, we discuss the major 
issues which we believe should be investigated in the future 
to improve our understanding of the role of IL-33 for tumor 
initiation/progression, toward the development of therapeutic 
strategies.
MAiN Review TeXT
iL-33 in Head and Neck Squamous  
Cancer (HNSCC)
Head and neck squamous cancer represents one of the six leading 
cancer types worldwide and it arises in the oropharynx, larynx, 
oral cavity, and hypopharynx. Major risk factors for the develop-
ment of HNSCC are alcohol consumption and tobacco smoke. 
However, infection with human papillomavirus (HPV) can also 
promote tumor development (36).
The tumor microenvironment appears to strongly contribute 
to HNSCC development. Cancer-associated fibroblasts (CAFs) 
are the most critical cells in the HNSCC microenvironment, 
which promote tumor cell proliferation, invasion, and metastatic 
potential. Therefore, CAFs determine HNSCC tumor aggres-
siveness. These CAFs release IL-33, which induces epithelial-to-
mesenchymal transition of cancer cells, thereby supporting their 
ability for migration and invasion. Furthermore, IL-33 induces 
IL33 gene expression in HNSCC cells via a positive feedback 
mechanism. Increased IL33 expression in CAFs and in tumor 
cells is associated with low patient survival (37). In patients 
with squamous cell carcinoma of the tongue, high expression 
of IL-33 or ST2 is indicative of worse prognosis. Increased IL-33 
levels in these tumors also correlate with microvessels in the 
stroma (38).
While these data suggest that IL-33 blockade may be beneficial 
for HNSCC patients, further investigations are required to define 
downstream key factors dependent on IL-33 for the develop-
ment of HNSCC. In particular, in  vivo experiments should be 
performed to validate these initial data.
iL-33 in Non-Small-Cell Lung  
Cancer (NSCLC)
Non-small-cell lung cancer is the most common type of lung can-
cers, representing more than 85% of all lung cancers. NSCLC has 
a predicted 5-year survival rate of 15.9%. Although the prognosis 
for NSCLC has only marginally changed the past years, under-
standing of the cellular and molecular mechanisms underlying 
the disease has greatly improved (39).
While many studies have shown a critical role of the IL-33/
ST2 signaling in inflammatory lung disease, including respiratory 
allergy, asthma, and chronic obstructive lung disease (19, 40–42), 
few have investigated the contribution of this pathway to lung can-
cer. In NSCLC patients, expression of IL33 and IL1RL1 was found 
to be increased in tumor tissue compared to adjacent non-tumor 
tissue, and this expression was associated with disease clinical 
stage (43). However, another study reports downregulation of 
IL33 and IL1RL1 in human lung cancer tissue and cells, compared 
to normal tissue and cells. Furthermore, the authors found that 
IL33 and IL1RL1 transcript levels were inversely correlated with 
stages of human lung cancers and overall survival. Accordingly, 
ST2 protein was expressed in low-metastatic, but not in high-
metastatic Lewis lung carcinoma (3LL) cells (44).
Mechanistically, in vitro stimulation with IL-33 or overex-
pression of IL33 in primary NSCLC cells enhanced their growth 
and metastasis after transfer into immunodeficient mice. 
Inversely, shRNA-mediated knockdown of IL33 in primary 
NSCLC cells limited their proliferation and invasion capacity 
in vivo. Corresponding results were obtained by overexpressing 
or downregulating IL1RL1 in NSCLC cells, thereby showing 
that the IL-33-driven tumor progression in this model relies 
on ST2. In addition, engagement of IL-33/ST2 signaling in 
NSCLC cells was found to increase the membrane expression 
of glucose transporter 1 (GLUT1) and thereby enhance their 
glucose uptake and lactate production. Finally, knockdown 
of SLC2A1/GLUT1 in NSCLC cells diminished their IL-33-
mediated proliferation as well as their metastatic potential, 
in vitro (43).
Yet, IL-33 may also trigger death of ST2-expressing lung 
tumor cells under conditions mimicking the tumor environment 
in  vitro, including upon nutrient depletion or under hypoxic/
anoxic conditions. This mechanism may possibly select for more 
malignant, ST2-negative cancer cells (44).
One can only speculate on the reason for the controversial 
findings in these two studies. Patient cohorts and cohort size were 
different in the two investigations. Moreover, no information 
was provided on the therapeutic status of the analyzed patient 
samples. Indeed, radiotherapy, alone or in combination with 
chemotherapy, belongs to the standard treatment of NSCLC (45), 
which can lead to a rapid increase in the expression of IL-33 pro-
tein in tissues (46). Thus, careful evaluation of patient therapeutic 
history is key for the study of IL-33 signaling in human samples. 
Finally, while one study describes the use of lung cancer cell lines, 
primary NSCLC cells were used in the other report, which makes 
a direct comparison difficult.
Therefore, additional studies are necessary to clarify the 
contribution of IL-33/ST2 signaling to lung cancer, in particular 
to NSCLC.
iL-33 in Breast Cancer
Breast cancer is one of the major causes of cancer-related death 
among women worldwide (47). Distant metastasis to the lung, 
bones, liver, and brain are causal for the death of breast cancer 
patients (48). The immune system has an ambivalent role in 
breast cancer as it may either promote or prevent tumorigen-
esis. Tumor-infiltrating leukocytes in particular have a strong 
effect on breast cancer development. While NK cells and CTLs 
mediate an anti-tumorigenic response in the microenvironment 
of breast tumors, Tregs and myeloid-derived suppressor cells 
(MDSCs) act in an immunosuppressive fashion [reviewed in 
Ref. (49)].
Several studies point toward a pro-tumorigenic role of IL-33/
ST2 signaling in breast cancer. IL-33 and ST2 expression are 
elevated in human breast cancer tissue compared to normal 
breast tissue (50, 51). In breast cancer patients, serum levels of 
IL-33 and of its decoy receptor sST2 were enhanced compared to 
healthy controls. This positively correlated with the expression of 
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vascular endothelial growth factor (VEGF), metalloprotease-11 
(MMP-11), or platelet-derived growth factor-C, which are mark-
ers of poor prognosis in breast cancer (52).
Compared to wild-type (WT) controls, Il1rl1-deficiency led to 
delayed tumorigenesis in mice tested in the syngeneic 4T1 breast 
cancer model. Moreover, after orthotopic injection of 4T1 cells, 
Il1rl1-deficient mice showed reduced metastatic potential to the 
lung and liver. This was caused by decreased tumor cell prolifera-
tion in Il1rl1-deficient mice. Accordingly, administration of IL-33 
in this model enhanced tumor cell proliferation in WT mice, 
through an indirect effect of IL-33 on tumor cells (53, 54).
In the 4T1 breast cancer model, IL-33 was expressed by 
CD45-positive leukocytes and tumor cells, while ST2 was mainly 
expressed on Tregs and type-2 ILCs (54). Furthermore, there were 
fewer MDSCs in tumor lesions of Il1rl1-deficient mice, while 
treatment with exogenous IL-33 promoted the accumulation of 
these suppressor cells in mammary tumors. MDSCs responded 
to IL-33 by increasing their production of immunosuppressive 
TGF-β (54). These MDSCs may be recruited from peripheral 
lymphoid organs to the tumor lesions, where they trigger the 
generation of CD4+ FoxP3+ Tregs (55). Indeed, the percentage of 
CD4+ FoxP3+ Tregs, especially the cells expressing ST2 and IL-10, 
was found to be enhanced within 4T1 mammary tumors.
In addition to these indirect pro-immunosuppressive mecha-
nisms, IL-33 signaling appears to also blunt tumor surveillance 
in the murine 4T1 breast cancer model. Indeed, NK cells showed 
increased IFN-γ production in Il1rl1−/− mice injected with 4T1 
breast cancer cells, which translated into improved antitumor 
immunity. Along the same line, administration of IL-33 reduced 
NK cell function via decreased expression of FasL or NKG2D 
and enhanced programed cell death protein 1 (PD-1) levels. IL-33 
also altered the ratio of dendritic cell subsets in 4T1 breast tumor 
lesions (54).
In other models, IL-33 also showed a direct action on malig-
nant breast cells. Stimulation with IL-33 enhanced proliferation 
as well as colony formation and size of a ST2-expressing breast 
cancer cell line. This occurred via a mechanism involving 
MAP3K8 phosphorylation upon engagement of IL-33/ST2 
signaling (51).
Together, these studies indicate that the IL-33/ST2 pathway 
promotes breast tumorigenesis both directly, via activation of 
cancer cells, and indirectly, via modulation of antitumor immu-
nity. Thus, the IL-33/ST2 pathway may represent an interesting 
target for breast cancer therapy.
iL-33 in Hepatocellular Carcinoma (HCC)
Hepatocellular carcinoma is one of the most prevalent cancers 
and it represents a prominent cause of mortality. Individuals with 
advanced fibrosis, cirrhosis, and hepatitis B are predisposed to 
HCC development. Patients with chronic hepatitis B and C infec-
tions are most commonly affected. The pathogenesis of HCC is 
a multistep and complex process, wherein angiogenesis plays an 
important role (56, 57).
Immuno-histochemical analysis revealed an increase in 
IL-33-positive tissue in HCC compared to normal liver tissue. 
In addition, IL-33 serum levels were higher in pre- and post-
operative serum samples from HCC patients compared with 
normal healthy controls (58). However, a different research group 
found no difference in IL-33 serum levels in HCC compared to 
liver cirrhosis patients and healthy controls, although levels of 
sST2 were significantly elevated in their liver cirrhosis and HCC 
patient groups compared to healthy controls. In HCC patients, 
serum sST2 levels correlated with overall survival (59).
Yet another study reports reduced levels of IL-33 protein in 
HCC compared to normal liver, hepatitis, and cirrhosis tissues. 
Moreover, while IL-33 was observed both in the nucleus and, to a 
lesser extent, in the cytoplasm of hepatocytes in normal liver tis-
sue, HCC showed only cytoplasmic IL-33 staining. IL-33 expres-
sion was negatively associated with HCC histological grade, but 
not with other parameters including lymph node metastasis. 
Together, this suggests that cytoplasmic/non-nuclear IL-33 might 
play a role in HCC development (60).
Although the mechanisms by which IL-33/ST2 signaling may 
contribute to HCC are still elusive, tumor-infiltrating, IL-33-
producing effector-memory CD8+ T cells have been observed in 
resected HCC tissue, which are associated with prolonged patient 
survival (61).
iL-33 in Cholangiocarcinoma (CCA)
Cholangiocarcinoma is a malignant neoplasm of the biliary-duct 
system that represents the second most common primary hepatic 
malignancy (62). Parasite infections, primary sclerosing cholan-
gitis, biliary-duct cysts, hepatolithiasis, and toxins are known 
risk factors of this type of cancer (62). Moreover, CCA is also 
associated with chronic inflammation.
Interleukin-33 has a promoting role for CCA. In a murine 
model of CCA based on biliary epithelium transduction of con-
stitutively active AKT and Yes-associated protein (YAP) together 
with bile duct ligation, administration of IL-33 increased biliary 
tumorigenesis (63). Mechanistically, ST2 protein was expressed 
in cancer cells and in CAFs, and IL-33 enhanced tumorigenesis 
through an increase of IL-6 expression in tumor tissue. Moreover, 
IL-6 was able to substitute for IL-33 in this model (63). IL-6 trig-
gers survival and mitogenic signals in CCA cells, in an autocrine 
or paracrine fashion (64, 65). Alternatively, administration of 
IL-33 to mice was found to enhance cholangiocyte proliferation, 
via a mechanism involving an increase in the number of IL-13-
producing type-2 ILCs. Activation of this IL-33/ILC2/IL-13 axis 
in animals with constitutive activation of AKT and YAP in bile 
ducts induced CCA with liver metastases (66).
Additional in  vivo experiments for instance using blocking 
antibodies are necessary to evaluate the relevance of the IL-33/
IL-6 or IL-33/IL-13 axis as therapeutic targets in CCA.
iL-33 in Gastric Cancer
Gastric cancer represents the fourth most common type of cancer 
and is the second leading cause of cancer-mediated death in the 
world (67). The 5-year overall survival of gastric cancer patients is 
only around 20% (68). Major risks for the development of gastric 
cancer are dietary factors, H. pylori infections, gastro-esophageal 
reflux disease, and obesity [reviewed in Ref. (68)]. Inflammation 
is an important contributor to gastric tumorigenesis, which is 
exemplified by the well-studied pro-tumorigenic role of H. pylori 
for this cancer. Indeed, bacterial virulence factors of H. pylori and 
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pathogen interaction with the host immune system result in a 
chronic inflammation that promotes tumorigenesis (69, 70).
Interleukin-33 appears to exert a pro-tumorigenic function in 
gastric cancer. Human gastric cancer cell lines stimulated with 
IL-33 showed a dose-dependent increase in cancer cell invasion 
and migration. These effects were abrogated by knocking-down 
IL1RL1. Engagement of IL-33/ST2 signaling in these gastric 
cancer cell lines activated ERK1/2 (71), a pathway known to be 
important for tumor invasion and metastasis (72). Moreover, 
IL-33 also triggered gastric cancer cells to secrete IL-6 and 
MMP-3 (71), factors with established pro-tumorigenic properties 
(73, 74).
Still, additional studies on human gastric cancer tissue and 
in  vivo experiments in mice are required to further assess the 
function of IL-33 for gastric cancer development and progression.
iL-33 in Colorectal Cancer (CRC)
Colorectal cancer represents one of the most common human 
cancer types, that is fatal in a considerable number of cases 
(75). CRC development is a multistep process that follows the 
adenoma-carcinoma sequence as a consequence of the accumula-
tion of alterations in key oncogenes and tumor suppressor genes 
involved in the Wnt/β-catenin-, KRAS-, MYC-, MAPK-, TGF- 
β/bone morphogenetic protein-signaling pathways—among 
others—and TP53 (76–78). Chronic inflammation strongly pro-
motes intestinal tumorigenesis (4), which is also illustrated by the 
fact that patients suffering from IBD have a higher risk to develop 
CRC (79, 80). In addition, several cytokines and inflammatory 
mediators have been shown to be associated with or to promote 
intestinal tumorigenesis (81).
While most studies have shown a pro-tumorigenic role of 
IL-33/ST2 signaling in CRC, recent data suggesting a protective 
role have also been published. We and others found increased 
levels of IL33 and IL1RL1 expression, both on the transcript 
and protein level, in adenoma and low grade adenocarcinoma 
of CRC patients, compared to adjacent normal tissue and high 
grade tumors (82, 83). Similarly, IL33 transcript levels were 
found to be higher in stage I–III CRC compared to adjacent 
normal colonic tissue. However, IL33 expression was lower 
in stage IV CRC than in stage I–III intestinal tumors (84). In 
contrast, another study reports progressively increasing levels 
of IL33 and IL1RL1 transcript from low to high grade and stage 
of human CRC (85).
In animal models, Il33 and Il1rl1 levels are elevated in adeno-
matous polyps of ApcMin/+ mice. In this model of CRC, Il33 defi-
ciency is associated with decreased growth of intestinal polyps 
(86). Similarly, in the azoxymethane (AOM)/dextran sodium sul-
fate (DSS) model of colitis-associated CRC (CAC), we found that 
IL-33/ST2 signaling promotes tumorigenesis. Indeed, Il1rl1−/− 
mice treated with AOM/DSS showed delayed CAC development, 
fewer/smaller tumors and lesions of lower grade, compared to 
WT controls. Experiments using bone marrow (BM) chimeric 
mice indicated that IL-33/ST2 signaling was engaged on both 
the radio-resistant and the radio-sensitive compartment (83). 
In a different model of CRC, syngeneic MC-38 colon carcinoma 
cells injected into the cecum of recipient mice showed enhanced 
growth and liver metastasis when overexpressing IL-33 (84).
Stimulation of human primary CRC cells with exogenous IL-33 
resulted in a dose-dependent increase in their invasive potential. 
In addition, IL-33 overexpression in these CRC cells resulted 
in an enhanced invasion, a mechanism dependent on signaling 
through ST2. These in vitro findings were confirmed by challeng-
ing nude mice with metastatic SW620 cells. Overexpressing IL33 
in SW620 cells injected subcutaneously enhanced their growth, 
metastasis, and reduced the survival of recipient nude mice, while 
downregulating IL33 had an opposite effect (85).
In human and murine CRC tissue, IL-33 is predominantly 
expressed by epithelial cells but also in endothelial cells and 
myofibroblasts. ST2 is mainly expressed on transformed epithelial 
cells, endothelial cells, myofibroblasts, and infiltrating immune 
cells (82, 83, 86, 87).
Mechanistically, IL-33 enhances the recruitment of 
CD11b+F4/80+ macrophages and CD11b+Gr-1+ MDSCs to 
CRC tumors. IL-33 also stimulates the secretion of S100A8/9 (a 
DAMP) and VEGF from these cell populations to support tumor 
angiogenesis and metastasis (84).
Several studies have reported an accumulation of mast cells 
in human and mouse intestinal adenomas, which promote 
polyposis in Apc mutant mouse models via stimulation of angio-
genesis, modulation of Treg function, and mobilization of MDSCs 
within the tumor microenvironment (88–90). Along these lines, 
Il33-deficient ApcMin/+ mice showed reduced accumulation of 
ST2-expressing mast cells in their polyps, compared to ApcMin/+ 
mice expressing Il33. In the same model, abrogation of IL-33/ST2 
signaling was associated with reduced expression of proteases 
and cytokines known to promote polyposis (86).
Stimulation of primary human CRC cells with IL-33 resulted 
in an increased secretion of IL-6, CXCR4, MMP-2, and MMP-9 
(85), which have all been involved in CRC metastasis (91–95). 
ApcMin/+ mice deficient in Il33 show reduced transcript levels 
of Il4 and Il6, which drive CRC development (81, 86). In addi-
tion, engagement of IL-33/ST2 signaling on radio-resistant 
cells decreases the integrity of the intestinal barrier and enables 
translocation of microbial products to the circulation. This was 
associated with enhanced systemic levels of pro-tumorigenic 
IL-6. Furthermore, hematopoietic cells isolated from the vicinity 
of CAC lesions and stimulated with exogenous IL-33 showed 
upregulated Il6 transcript levels. Therefore, the IL-33/ST2 axis 
contributes to colorectal tumorigenesis partly via increased 
production of IL-6 (83).
Epidermal growth factor (EGF) appears to regulate Il33 
expression in intestinal epithelial cells. In tumors of AOM/DSS-
challenged mice treated with gefitinib, an inhibitor of epidermal 
growth factor receptor, Il33 transcript levels were decreased, 
compared to untreated controls. This correlated with fewer and 
smaller tumors in this model. EGF stimulation of an intestinal 
epithelial cell line increased its expression of ST2 and intracellular 
IL-33 (87). This suggests a link between EGF and the IL-33/ST2 
signaling axis and may provide a target for the treatment of CRC, 
although this requires further investigation.
In contrast to the above-presented findings, two recent 
studies reported an anti-tumorigenic role of IL-33/ST2 signal-
ing for intestinal tumorigenesis. In a first report, expression 
of transmembrane ST2 was found to be lower in human CRC 
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compared to adjacent, non-tumor tissue, and it progressively 
decreased during tumor progression from Stage I to Stage IV 
CRC. While shRNA-mediated knockdown of Il1rl1 did not alter 
the proliferation or migration of CT26 CRC cells in vitro, these 
cells developed larger tumors when injected into the flanks of 
immunocompetent recipient mice. This correlated with a reduc-
tion of macrophage recruitment to the tumor tissue, likely due 
to diminished CCL2 production by tumor cells with abrogated 
IL-33/ST2 signaling (96). In a second report, IL-33 was shown 
to promote IgA production, thereby preventing microbial dys-
biosis and IL-1α-dependent inflammation in the intestine. Upon 
AOM/DSS treatment of Il33-deficient mice, this translated in 
augmented secretion of inflammatory cytokines as well as tumors 
of increased number, size, and grade, compared to WT mice 
(97). However, it is currently not known whether IL-33 fulfills 
a similar function in the human intestine, where manipulation 
of the microbiota may represent a therapeutic strategy for the 
treatment of CRC, independently of IL-33 (81).
Taken together, the ambivalent role of IL-33/ST2 signaling for 
CRC tumorigenesis in mouse models makes it difficult to assess 
this pathway as a possible target for CRC therapy in humans. 
It seems important to compare the different murine models 
presented above side-by-side. Moreover, additional experiments 
should be performed that involve blockade of the IL-33/ST2 path-
way at different stages of CRC progression. Also, chemotherapy 
may differently affect ST2 and IL-33 levels in CRC patients (96), 
which should be considered in the design of future human studies 
on these molecules.
iL-33 in Myeloproliferative  
Neoplasms (MPNs)
Myeloproliferative neoplasms constitute a group of chronic 
hematologic malignancies which are characterized by an 
abnormal proliferation of myeloid cells (98). They are classified 
as BCR-ABL1-positive MPN, for chronic myeloid leukemia 
(CML), or BCR-ABL1-negative MPNs, which mainly comprise 
polycythemia vera, essential thrombocythemia, and primary 
myelofibrosis (98, 99). Most cases of BCR-ABL-negative MPNs 
present a mutation in a molecule involved in JAK/STAT signal-
ing (100). As a consequence of these diverse genetic aberrations, 
cytokine signaling is dysregulated in both classes of MPNs (98).
Interleukin-33/ST2 signaling supports the development of 
both BCR-ABL1-positive and -negative MPNs. Increased levels 
of nuclear IL-33 protein are present in trephine biopsies of BCR-
ABL1-negative MPN patients, and high amounts of circulating 
soluble ST2 were detected in the plasma from CML patients, 
compared to controls. Furthermore, ST2 is upregulated on the 
surface of CD34+ hematopoietic stem/progenitor cells (HSPCs) 
of BCR-ABL1-positive and -negative MPN patients, compared 
to healthy donors (101, 102). Addition of exogenous IL-33 
increased the colony forming potential of CD34+ HSPCs of MPN 
patients (102).
In mouse models, we found that IL-33 supports MPN-like 
disease and myeloproliferation in mice deficient in Inppd5 or 
in irradiated recipients transfused with BM cells transgenic for 
human JAK2V617F, one of the most common driver mutations in 
MPN patients (102). CD34+ HSPCs from CML patients engrafted 
better in immunodeficient mice after pre-treatment with IL-33, 
and BCR-ABL-expressing BM cells showed reduced ability to 
induce CML-like disease when transplanted into Il33-deficient 
versus Il33-competent recipients (101).
Interleukin-33 is expressed in radio-resistant cells, including 
endothelial cells, in the BM. ST2 expression in the BM is mainly 
restricted to endothelial, mesenchymal, and early myeloid cells. 
Importantly, ST2 was not detected on murine HSPCs. The 
IL-33/ST2 pathway in the BM can be activated both in stromal/
non-hematopoietic and in hematopoietic cells. Engagement 
of ST2 on these cells leads to secretion of cytokines known to 
promote the development and proliferation of myeloid cells, 
including IL-6, GM-CSF, G-CSF, and IL-3 (102). Since human 
CD34+ HSPCs express ST2, they are able to directly respond to 
IL-33 stimulation in vitro, which induces cytokine production 
and subsequent cell proliferation (101, 102). These cytokines, in 
turn, activate the STAT5 pathway and can confer resistance to 
imatinib mesylate, a specific kinase inhibitor of the BCR-ABL1 
fusion protein (101).
While these data suggest a potential therapeutic benefit in 
blocking IL-33/ST2 signaling in MPNs, additional experiments 
should first assess the role of this pathway for disease progression 
and drug resistance in MPN patients.
iL-33 As immune Adjuvant for  
vaccine Therapy
Except for a few particular examples presented above, IL-33 
has mainly a pro-tumorigenic function for cancer development 
(96,  103). However, IL-33 may also function as an immune 
adjuvant for antitumor immune response. Indeed, IL-33 has been 
shown to promote potent cancer-specific effector and memory 
T cell immunity when used as an adjuvant for DNA vaccination 
in mice (104). This is in line with findings indicating that IL-33 
increases the numbers of CD8+ T cells and NK cell-producing 
IFN-γ in transgenic B16 tumors overexpressing IL-33, thereby 
mediating a microenvironment favoring tumor rejection. 
However, IL-33 also promoted the accumulation of immunosup-
pressive ST2-expressing Tregs in this model (103).
Interestingly, aluminum-based adjuvants (alum) induce 
cell necrosis that leads to extracellular release of IL-33 and the 
subsequent induction of several IL-33-dependent inflammatory 
cytokines. In addition, IL-33 injected together with the NP-CGG 
model antigen increased NP-specific IgM titers in the primary 
response and T cell-dependent NP-specific IgG1 titers after anti-
gen boost. This indicates that IL-33 can induce robust antigen-
specific antibody responses (105). IL-33 was also reported to 
reduce the accumulation of MDSCs in the spleen and tumor 
microenvironment, and to decrease the immunosuppressive 
activity of these cells, which limited tumor growth (106).
Together, these findings indicate the possible use of IL-33 as an 
immune adjuvant. Yet, there may be some challenges in applying 
IL-33 for immunomodulation or vaccination, as high levels of 
IL-33 may lead to lethal inflammatory disease in mice (107, 108). 
Therefore, it might be difficult to find the right dose of IL-33 to 
support the desired antitumor-specific immune response while 
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avoiding exacerbated inflammation. This may restrict the pos-
sibility of using IL-33 in a vaccine setting.
iL-33 As Tumor Biomarker or  
Therapeutic Target
As presented above, IL-33 contributes to the modulation of the 
tumor environment by promoting the recruitment of pro-tumo-
rigenic immune cells or the secretion of tumorigenic cytokines. 
However, IL-33 can be detected not only in the tumor environ-
ment, but also in the serum of cancer patients. For instance, 
IL-33 levels are increased in the serum of lung and gastric cancer 
patients and correlate with disease stage, suggesting that IL-33 
may be a negative prognostic marker for these types of cancer 
(109, 110). Moreover, expression levels of IL33 and ST2 correlate 
with tumor grade and inferior survival of glioblastoma patients 
(111). However, IL-33 expression indicates favorable prognosis 
in patients with malignant salivary gland tumors (112). In addi-
tion, loss of IL33 expression may also promote tumor escape 
in patients with metastatic prostate carcinomas or kidney renal 
clear cell carcinomas, via down-modulation of genes involved 
in antigen processing and of major histocompatibility complex 
(MHC-I/HLA)-genes (113). Therefore, IL-33 and ST2 differently 
contribute to tumorigenesis depending on the nature of the 
malignant tissue.
For breast cancer, IL-33 and sST2 may also serve as non-
invasive diagnostic marker, as these two proteins are upregulated 
in the serum of patients [(52) and see also the paragraph on breast 
cancer above]. However, IL-33 is upregulated in different types 
of inflammatory diseases (114–116) and cancers (111, 112), and 
this lack of specificity may prevent its use as a biomarker in the 
daily clinic diagnostic. Furthermore, while high levels of IL-33 
in absence of common markers of inflammation may indicate 
the presence of cancer, it would not indicate the identity of the 
cancerous tissue, and more specific markers would be addition-
ally required for diagnostics. Another level of complexity comes 
from the observation that the IL-33/ST2 pathway appears to be 
differently regulated during the progression of distinct types of 
cancers, as mentioned just above.
While cytokine blockade is currently applied for the treat-
ment of inflammatory disorders, including for instance the use 
of antitumor necrosis factor-α monoclonal antibodies to treat 
ulcerative colitis and Crohn’s disease, it remains to be investigated 
whether a blockade of the IL-33/ST2 pathway may represent a 
valid approach for the therapy of established IL-33-dependent 
tumors. Experimental evidences are currently lacking that clearly 
indicate the suitability of such an approach. Alternatively, IL-33 
blockade might be applied in combination with other (immuno)
therapies. As IL-33 mainly acts as an amplifier of inflammation 
(117), targeting IL-33 may suppress the pro-tumorigenic inflam-
mation in the tumor stroma, therefore improving the treatment 
with conventional therapies. For instance, combination of 
imatinib and IL-33 blockade in CML may allow elimination of 
cytokine-dependent malignant stem cells (118) or prevent the 
emergence of drug resistance (101). Along these lines, combined 
administration of IL-33 and PD-1 blockade was recently shown 
to improve the survival of mice suffering from acute myeloid 
leukemia (119).
CONCLUSiON AND DiSCUSSiON
The tumor microenvironment represents a critical incubator for 
tumor development, local invasion, and metastasis (3). This envi-
ronment can be modulated by different factors including pro- or 
anti-tumorigenic cytokines (15). The alarmin IL-33, an amplifier 
of innate immune response (117), has been shown to contribute 
to different types of inflammatory diseases and more recently to 
modulate tumorigenesis (Figure  2) (35, 42). Several investiga-
tions using patient-derived material, in  vitro approaches, or 
in vivo models have uncovered a differential role of the IL-33/ST2 
pathway in the tumor microenvironment, for tumor initiation, 
development, and resistance to therapy (Table 1). While IL-33 
has generally a pro-tumorigenic function in various cancers, for 
some cancer types the findings generated so far are controversial. 
We discuss below possible reasons for these discrepancies and 
how they may be possibly addressed or resolved.
Different iL-33- and ST2-expressing Cell 
Types in the Tumor environment
Several of the expression studies presented above analyzed whole 
tumor tissues, without distinction of the different IL-33- and ST2-
expressing cell types in the tumor microenvironment. However, 
not only transformed cells, but also infiltrating immune cells, 
endothelial cells, or myofibroblasts may express IL-33 or ST2 in 
the tumor stroma (54, 83, 86, 102, 120). Therefore, the presence 
or contribution of these non-cancerous cells should be separately 
evaluated for future correlative or functional studies.
The relevance of IL-33- and ST2-expressing non-cancerous 
cells to tumorigenesis may also explain the contradictory out-
comes from distinct animal models. Indeed, xenograft studies 
are not suitable to address the contribution of stromal cell-
specific IL-33/ST2 signaling to tumorigenesis. While there is a 
55% homology (19) and a 66% identity at the amino-acid level 
between human and murine IL-33 and ST2, respectively, it is 
not known whether these molecules can cross-react between the 
two species. Moreover, immune cells can engage ST2 upon IL-33 
binding, whose contribution cannot be assessed using immu-
nocompromised animals as recipients of xenografts. Finally, for 
certain types of cancers, heterotopic models may not properly 
address the role of the physiologic tumor microenvironment. This 
holds true in particular for CRC, since IL-33 can control dysbiosis 
in the intestine, which in turn impacts on colon tumorigenesis 
(97)—a parameter likely omitted by studies involving subcutane-
ous application of CRC cells. Therefore, these limitations shall 
be taken into account, especially when evaluating the clinical 
relevance of the different findings.
Spatiotemporal Contribution of iL-33  
and ST2 to Tumorigenesis
Interleukin-33 may differently contribute to tumorigenesis in 
dependence on where it is available. As presented above, local 
IL-33 in the tumor microenvironment can directly trigger cancer 
or stromal cells. However, IL-33, in particular when given exog-
enously, may drain to the lymph nodes, where it can promote 
antitumor responses—as shown in several immune adjuvant 
vaccine studies (see the above paragraph on IL-33 as immune 
FiGURe 2 | Role of interleukin-33 (iL-33) in the tumor microenvironment. (A) In breast cancer (mouse 4T1 breast cancer model), IL-33 is released by tumor 
cells and acts in an autocrine/paracrine manner. In addition, IL-33 promotes the recruitment of immunosuppressive cells and inhibits the function of antitumor 
cytotoxic natural killer cells (NK). (B) In gastric cancer, IL-33 may promote vessel invasion of tumor cells by stimulating the secretion of IL-6 and MMP-3 through 
activation of the ERK pathway. (C) In colorectal cancer, IL-33 supports the recruitment to the tumor environment of pro-tumorigenic immune cells, including mast 
cells and myeloid-derived suppressor cells (MDSCs). In addition, IL-33 promotes the secretion of pro-tumorigenic IL-6 by leukocytes in the tumor vicinity, which are 
possibly CD11c+ dendritic cells. (D) In patients with myeloproliferative neoplasms, IL-33 is released by bone marrow stromal and endothelial cells, and it engages 
ST2 on CD34+ hematopoietic stem/progenitor cells, thereby promoting their secretion of IL-6 and GM-CSF. These cytokines, in turn, stimulate in an auto/paracrine 
manner the uncontrolled proliferation of the malignant clone (due to its defect in JAK/STAT signaling).
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adjuvant). While this has still to be demonstrated, systemic IL-33 
may also possibly keep ST2-expressing immunosuppressive cells 
at sites distant from (IL-33-expressing) tumors, thereby “distract-
ing” them from their pro-tumorigenic role. Indeed, in vivo IL-33 
administration can restrict the accumulation of MDSCs in the 
tumor microenvironment (106).
Finally, IL-33/ST2 signaling may contribute to different stages 
of tumorigenesis, including tumor growth or metastasis, and 
additional genetic tools are needed to systematically dissect the 
role of this pathway at specific time points of cancer development.
Regulation of iL-33 Release—Role  
of iL-33 As a Cytokine
As IL-33 may become upregulated in different types of cells upon 
malignant transformation, its mere presence in tumors should 
not always imply engagement of ST2-dependent signaling, which 
may also explain conflicting findings across studies. IL-33 first 
needs to be released extracellularly before binding to its receptor. 
However, the exact mechanisms for the regulation and release 
of IL-33 are still elusive, and they may vary between distinct 
experimental settings or models. Indeed, in addition to cell dam-
age/necrosis-dependent release of IL-33, IL-33 may also become 
actively released. Stress conditions associated with increased 
extracellular adenosine triphosphate (ATP) (a DAMP) may trig-
ger IL-33 secretion after activation of purinergic receptor P2Y2R 
signaling in live cells (40, 121). Moreover, alternative splicing-
mediated deletion of exon 3 and 4 of IL33 transcripts confers 
cytoplasmic localization of IL-33 proteins, which facilitates its 
extracellular secretion from airway epithelial cells of asthmatic 
patients. Importantly, this isoform of IL-33 was shown to retain 
its ability to signal through ST2 (122). Thus, it is conceivable that 
such IL-33 isoforms are also preferentially produced by tumor 
cells (or cells in the tumor microenvironment), a hypothesis that 
remains to be addressed. Detectable amounts of IL-33 can be 
measured in the serum of healthy patients (123) and naïve mice 
(102) suggesting that IL-33 is released and circulates even under 
TABLe 1 | interleukin-33 (iL-33) and ST2 levels and contribution in different cancers.
Net effect of
iL-33 ST2
Type of cancer expression Tumor 
progression
Metastasis expression Tumor 
progression
Metastasis Major references
Head and neck squamous cancer Human + + (37, 38)
Non-small lung cancer Human + + + + + + (43)
− − − − (44)
Breast cancer Human + + (50, 51)
Mouse + + + (53, 54)
Hepatocellular carcinoma Human + + + (58, 59)
Cholangiocarcinoma Mouse + + + (63, 66)
Gastric cancer Human + + + + (71)
Colorectal cancer Human + + + + + (82, 83, 85)
− − (96)
Mouse + + + + + (83, 84, 86)
− − (96, 97)
Myeloproliferative neoplasms Human + + + (101, 102)
Mouse + + (102)
+, promoting effect; −, suppressing effect.
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steady-state conditions (Figure 1). Thus, such basal level of IL-33 
may also help amplify the inflammatory milieu in chronic inflam-
matory disorders, which have been shown to provide favorable 
conditions for the development of tumors (4). Therefore, cancer 
studies aiming at evaluating the role of IL-33 as a cytokine should 
systematically assess the function of ST2 in a particular experi-
mental model.
Role of iL-33 As a Transcriptional 
Regulator
In addition to its extracellular role as an alarmin triggering ST2, 
signaling, IL-33 also has a nuclear function. Indeed, IL-33 has been 
early reported to be expressed in the nucleus of epithelial barrier 
tissues and lymphoid organs (20, 124). Nuclear IL-33 binds to the 
p65 subunit of NF-κB, thereby reducing NF-κB-dependent gene 
expression (22). A study using fibroblast-like synoviocytes from 
patients with rheumatoid arthritis indicated that downregulation 
of IL-33 results in increased NF-κB activity and in the production 
of pro-inflammatory molecules. These results suggest that nuclear 
IL-33 transcriptionally represses NF-κB and down-modulates 
inflammatory responses (125). Importantly, NF-κB signaling is 
not only central for innate immunity and inflammatory processes; 
it also plays an important role for cancer initiation and progres-
sion (4, 126). Therefore, it may be particularly relevant to address 
the contribution of intracellular IL-33 to NF-κB signaling in 
tumorigenesis, which has so far not been investigated. As nuclear 
IL-33 generally becomes upregulated in response to inflamma-
tion (40, 127), this may provide a possible control mechanism via 
a negative feedback loop. However, the physiological relevance 
of this mechanism should be assessed experimentally, as nuclear 
IL-33 has only limited potential for binding active NF-κB and 
thus preventing it from binding to DNA (22).
Therefore, this nuclear function of IL-33 may explain why 
certain investigations using St2-deficient mice may not fully 
recapitulate the findings from Il33−/− animals. While the role of 
nuclear IL-33 needs to be further addressed, e.g., for possible 
interaction with cancer-relevant transcription factors additional 
to NF-κB, modulation of nuclear IL-33 expression likely repre-
sents a technical challenge for therapy.
Taken together, IL-33/ST2 signaling appears to mainly have 
a pro-tumorigenic role in cancer. However, several controversial 
reports provide caveats to a precipitated development of thera-
peutic strategies to block this pathway, and additional studies are 
required to unambiguously assess the contribution of IL-33 and 
ST2 to different cancer types.
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